Are NAD Injections Safe? Risks and Side Effects

NAD+ injections, typically given as slow intravenous infusions, produce real and often uncomfortable side effects in the short term, and their long-term safety has not been established in clinical trials. The small pilot studies that exist paint a consistent picture: most people receiving an NAD+ IV experience moderate to severe gastrointestinal symptoms, chest pressure, and elevated heart rate during the infusion itself, with symptoms resolving quickly once the drip stops. Whether the injections deliver lasting health benefits beyond temporarily raising blood levels of the molecule remains an open question, and the gap between what clinics promise and what the science supports is wide.

What NAD+ Is and Why People Seek Injections

Nicotinamide adenine dinucleotide (NAD+) is a molecule involved in hundreds of metabolic reactions throughout your body. It helps convert food into energy and serves as a helper molecule for enzymes that maintain DNA repair, circadian rhythm, and cellular stress responses. Research in animals has shown that NAD+ levels in tissues tend to drop with age, and restoring those levels in rodents has shown promise against various age-related conditions.¹ That animal research, combined with the broader anti-aging wellness movement, has driven intense consumer interest in NAD+ supplementation.

The most common routes people use to boost NAD+ are oral supplements (usually precursors like nicotinamide riboside or NMN) and intravenous infusions of NAD+ itself. IV clinics market NAD+ drips for energy, mental clarity, addiction recovery, and anti-aging. The appeal of the IV route is straightforward: it bypasses digestion and delivers the molecule directly into your bloodstream. But that directness comes with trade-offs, and the assumption that “more NAD+ in the blood equals better outcomes” has not been validated by rigorous human trials.²

What an NAD+ Infusion Actually Feels Like

If you have read anecdotal accounts online describing NAD+ IVs as intensely unpleasant, the clinical data backs that up. In a retrospective pilot study comparing NAD+ IV to nicotinamide riboside (NR) IV, every single participant in the NAD+ group reported moderate to severe abdominal cramping, diarrhea, nausea, vomiting, increased heart rate, throat pain, congestion, and chest pressure during the infusion.³ That was six out of six people, not an unlucky minority.

A separate randomized, placebo-controlled pilot study found the same pattern. The majority of NAD+ IV patients described their comfort level as “low.” They reported anxiety, headaches, nausea, and sudden urges to have a bowel movement. Nursing staff documented additional complaints including feeling “gassy,” muscle weakness, and stomach cramping. Roughly half the patients receiving NAD+ IV had a bowel movement during the infusion itself.⁴ Patients described the experience with phrases like “chest tightness and a little woozy,” “hot flashes,” and “feeling queasy.”

The silver lining, such as it is: these adverse experiences ceased immediately once the infusion was stopped.⁵ So the discomfort is transient, not lasting. But an infusion session typically runs two to four hours, which means you could be experiencing waves of nausea, cramping, and chest pressure for a significant stretch. Clinics often slow the drip rate to manage symptoms, which extends the session further.

NAD+ IV Compared to Its Precursor Alternatives

One of the more useful findings from recent pilot studies is the head-to-head comparison between intravenous NAD+ and intravenous nicotinamide riboside (NR), an NAD+ precursor that your body converts into NAD+ through enzymatic steps. The difference in tolerability is stark. While all NAD+ IV recipients experienced moderate to severe symptoms, only some NR IV recipients experienced any discomfort at all, and what they did report was much milder: tingling in the tongue, jaw, and arms, and minor cramping.³

In the placebo-controlled pilot, NR IV was associated with fewer and less severe adverse experiences during infusion. No attributable adverse events were reported through the 14-day follow-up period for any treatment group, including NAD+ IV, which suggests there were no lingering harms after the infusion ended. But the during-infusion experience was dramatically worse for the NAD+ group.⁴

A trial studying NR injections given subcutaneously (under the skin rather than into a vein) found that participants tolerated the shots reasonably well. Pain lasting more than two minutes after the injection was reported by about 46% of participants, and muscle soreness and tightness by about 43%, regardless of the dose or injection site. Blood pressure, blood chemistry, and organ function markers remained generally stable throughout both trials. Researchers concluded that the injections “were associated with some discomfort but were well tolerated and did not produce any concerning safety signals.”⁶ This is a meaningfully different safety profile from NAD+ delivered intravenously.

Blood Pressure and Heart Effects

The chest pressure and elevated heart rate that NAD+ IV recipients commonly describe naturally raise the question of cardiovascular safety. In the tolerability pilot, researchers found no significant change in systolic or diastolic blood pressure for either the NAD+ or NR group over four days of infusion.⁵ The NR subcutaneous injection trials observed some reductions in systolic blood pressure, but the researchers cautioned that the samples were too small and the baseline values too unbalanced to draw firm conclusions, noting the finding should be evaluated in larger studies.⁶

The heart rate increases people feel during NAD+ infusions appear to be transient and resolve when the drip stops. But none of these studies involved people with pre-existing heart conditions, arrhythmias, or uncontrolled blood pressure. If you have a cardiovascular history, the acute stress of an NAD+ infusion is a genuine unknown, and no study has been designed to answer whether it is safe for that population.

Kidney and Liver Safety

Concerns about organ toxicity from NAD+ boosting have received at least some attention, though mostly through studies of oral precursors rather than direct IV NAD+. A randomized, double-blind, placebo-controlled study gave escalating doses of nicotinamide riboside with pterostilbene (NRPT) to patients with acute kidney injury, a population where kidney function is already compromised. All safety lab tests remained unchanged by the treatment, including creatinine, estimated kidney filtration rate, electrolytes, liver function tests, and blood counts.⁷

That is reassuring as far as it goes, but it covers a specific oral precursor combination over a limited trial period, not repeated IV infusions of NAD+ itself. The distinction matters because the pharmacokinetics are different: an IV push delivers a sudden high concentration of the molecule into the bloodstream, which the kidneys and liver then have to process. Whether doing that weekly or monthly for years creates a cumulative burden on those organs is simply not known.

The Cancer Question

This is the concern that gets the least airtime in wellness marketing but arguably deserves the most. NAD+ is not just fuel for healthy cells. Cancer cells, which have high metabolic demands, also rely heavily on NAD+ to sustain their rapid growth. Research has shown that increased NAD+ levels enhance glycolysis and can fuel cancer cells. The enzyme responsible for a key step in NAD+ synthesis is frequently amplified in several types of cancer, and drugs that specifically block that enzyme deplete NAD+ levels and suppress cancer cell proliferation by starving them of energy.⁸

This creates an uncomfortable paradox. If you are flooding your body with NAD+ to “fight aging,” you might simultaneously be providing fuel for any cancerous or pre-cancerous cells that happen to be present, and nearly everyone over 40 carries some pre-cancerous cell populations. The oncology research community has been exploring NAD+ depletion as a cancer treatment strategy, which is the exact opposite direction from what wellness clinics are selling. No human study has demonstrated that NAD+ supplementation causes cancer or accelerates existing tumors, but no long-term study has been designed to rule it out, either. Given the biological plausibility of the concern, this is a gap that should make anyone considering regular NAD+ infusions pause.

Inflammation and Immune Effects

Preclinical studies of nicotinamide riboside (an NAD+ precursor) have generally shown a decrease in key inflammatory markers, with most animal studies reporting drops in TNF-α, IL-1β, and IL-6, molecules that drive inflammation when elevated.⁹ On the surface, that sounds beneficial. Chronic low-grade inflammation is linked to aging, heart disease, and metabolic dysfunction, so reducing it seems like a clear win.

But immune modulation cuts both ways. Your inflammatory response exists for a reason: it fights infections and helps identify and destroy abnormal cells, including early cancers. Whether suppressing these pathways is a net positive depends entirely on context, and the research here is still almost entirely in animals. A handful of the NR injection trials noted reductions in high-sensitivity C-reactive protein (a marker of inflammation) in some treatment arms, but researchers explicitly called those findings “hypothesis-generating” given the small sample sizes and baseline imbalances between groups.⁶ In other words: interesting, not proven.

The Long-Term Data Problem

The most honest thing anyone can say about the long-term safety of NAD+ injections is that we do not know. The studies that exist are small pilot trials, often with fewer than a dozen participants per group, running for days to weeks. No trial has followed people receiving regular NAD+ infusions for months or years to track outcomes like cancer incidence, cardiovascular events, or metabolic changes. A review in Antioxidants put it plainly: given the lack of long-term safety studies, more clinical trials are needed to determine proper dosing and treatment duration for NAD+ boosters both for aging prevention and disease therapy.¹⁰

This is not the kind of uncertainty where the science is leaning strongly one way and just needs a larger study to confirm. It is uncertainty where the basic direction of the effect on major health outcomes has not been established. When wellness clinics frame NAD+ infusions as “restoring what your body naturally loses,” they are describing a real biological observation about declining NAD+ levels, but jumping from “levels decline with age” to “replacing them is safe and beneficial” requires evidence that does not yet exist. Plenty of things change with age. Not all of those changes are problems, and not all interventions to reverse them turn out to be safe. Hormone replacement therapy is the canonical cautionary tale here.

Quality Control and Regulatory Gaps

NAD+ infusions exist in a regulatory gray zone. In most countries, these are administered at wellness clinics or by mobile IV services, not in hospital settings or under clinical trial oversight. The NAD+ used is typically sourced from compounding pharmacies, which are subject to less rigorous manufacturing standards than pharmaceutical manufacturers. There is no FDA-approved NAD+ injectable product, which means no regulatory body has evaluated the purity, stability, or sterility of what clinics are actually putting into your veins.

This matters more than you might expect. NAD+ and its precursors are chemically finicky molecules. Research on nicotinamide riboside chloride, for instance, has shown that it degrades upon melting and breaks down in solution through a process that produces nicotinamide, a degradation product that can actually antagonize the intended effect. The researchers emphasized that any formulation would need to protect the molecule from hostile environments to prevent accumulation of that antagonistic byproduct.¹¹ If the compound degrades in carefully controlled laboratory conditions, imagine what can happen in a compounding pharmacy with variable storage temperatures and handling protocols. You may not be receiving what you think you are receiving, and unlike a pill that passes through your gut, a degraded IV solution goes straight into your blood.

Who Should Be Most Cautious

Given the current state of the evidence, certain groups face higher potential risk from NAD+ injections than the general “healthy adult curious about anti-aging” population:

Cancer survivors or those with a family history of cancer: The biological plausibility that elevated NAD+ could fuel tumor growth makes this group a poor fit for an intervention that has never been studied in a cancer-relevant context.
People with heart conditions: The acute cardiovascular symptoms during infusion, including chest pressure and heart rate spikes, have only been observed in healthy volunteers. No safety data exists for people with arrhythmias, heart failure, or coronary artery disease.
Anyone on medications metabolized by the liver: Because NAD+ participates in so many metabolic pathways, the potential for drug interactions is theoretically large but has not been systematically studied.
People with autoimmune conditions: Modulating inflammatory pathways through NAD+ boosting could worsen or improve autoimmune activity. The honest answer is that nobody knows.

What the Subjective “Benefits” May Really Be

Many people who undergo NAD+ infusions report feeling more energetic or clear-headed afterward. The placebo-controlled pilot study offers a useful lens on these reports. The study included a saline placebo group, and the design allows you to see whether self-reported outcomes track with the actual treatment. The study’s primary focus was on safety and tolerability, not efficacy for subjective wellness, but the very fact that NAD+ IV produces such intense physical sensations during the infusion creates a problem for interpreting any post-infusion “boost.” You cannot blind someone to a treatment that makes them nauseated and crampy for two hours. If you know you received the real thing (because the experience was unmistakable), your expectation of benefit rises accordingly.⁴

There is also the rebound effect to consider. When you spend hours feeling terrible during the infusion and then the symptoms abruptly cease, the contrast between “actively miserable” and “normal” can register as “I feel amazing.” This is a well-understood perceptual phenomenon and does not require any pharmacological benefit to explain. That does not mean NAD+ infusions do nothing. It means the current evidence cannot separate a genuine effect from these confounders, and until properly blinded trials with validated outcome measures are completed, the subjective reports should be treated with healthy skepticism.

Chemical Stability During the Infusion Itself

A less obvious concern that rarely comes up in clinic marketing materials is what happens to NAD+ while it sits in the IV bag. NAD+ in solution is not particularly stable. If the bag has been prepared hours in advance, stored at the wrong temperature, or mixed with an incompatible solution, some portion of the molecule may have already degraded before it enters your vein. The degradation research on the related compound nicotinamide riboside chloride demonstrated that breakdown happens in solution and produces byproducts that can work against the intended effect.¹¹ Without standardized preparation protocols and real-time quality testing, which most wellness clinics do not perform, the actual composition of the fluid entering your bloodstream is uncertain. This is a practical safety concern that persists even if NAD+ itself turns out to be pharmacologically safe, because the question shifts from “is NAD+ safe?” to “is whatever is actually in this bag safe?”